Related Experiment Video
Updated: Aug 24, 2025
08:32
Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
13.0K
Beyond eNOS: Genetic influence in NO pathway affecting drug response
Aline Esposito1, Cezar Kayzuka Cotta Filho1, Riccardo Lacchini2
1Universidade de São Paulo, Departamento de Farmacologia, Ribeirão Preto, São Paulo, SP, Brazil.
Genetics and Molecular Biology
|October 20, 2022
Summary
Genetic variations in nitric oxide (NO) pathways beyond NOS3 influence drug response. Investigating genes like ARG1, ARG2, DDAH1, DDAH2, and VEGF offers insights into personalized pharmacotherapy.
Area of Science:
- Pharmacogenomics
- Nitric Oxide Biology
- Drug Response Variability
Background:
- Nitric Oxide (NO) plays crucial roles in biological functions and mediates drug responses.
- Genetic polymorphisms influencing NO production can significantly impact drug efficacy and safety.
- Current research predominantly focuses on the NOS3 gene, potentially overlooking other key genetic factors.
Purpose of the Study:
- To review literature on genetic polymorphisms in non-NOS3 genes affecting NO levels and drug response.
- To explore the impact of variations in Arginases (ARG1, ARG2), DDAH1, DDAH2, and VEGF on NO-mediated pharmacotherapy.
- To highlight the broader genetic landscape influencing NO-driven drug responses.
Main Methods:
- Systematic literature search on PubMed.
- Inclusion of 17 manuscripts assessing genetic polymorphisms in ARG1, ARG2, DDAH1, DDAH2, and VEGF.
- Analysis of study results concerning NO pathways and pharmacological agents.
Main Results:
- Evidence suggests that genetic polymorphisms in ARG1, ARG2, DDAH1, DDAH2, and VEGF influence NO-mediated drug responses.
- These findings indicate that NO-driven pharmacological effects are modulated by a wider range of genes than previously emphasized.
- The reviewed studies provide a foundation for understanding genetic variability in NO-related drug therapies.
Conclusions:
- Pharmacotherapy involving NO is influenced by genetic factors beyond the NOS3 gene.
- Identifying genetic markers in pathways like Arginase, DDAH, and VEGF can enhance understanding of drug response variability.
- Targeting these genetic variations may lead to safer and more effective NO-related pharmacotherapies.
More Related Videos
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
5.1K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.1K
01:21Factors Affecting Drug Response: Overview
2.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
01:29Drugs Affecting Neurotransmitter Synthesis
1.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.5K
01:23Antihypertensive Drugs: Vasodilators
619
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
619
01:16Antianginal Drugs: Nitrates and β-Blockers
702
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
702
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K